Romiplostim
First Progression of MGMT Promoter-methylated Glioblastoma
European Organisation for Research and Treatment of Cancer - EORTCprotein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
353 Active assets in the First Progression of MGMT Promoter-methylated Glioblastoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Beijing Sanbo Brain Hospital | Phase 2/3 | BBB |
Depatuxizumab Mafodotin AbbVie | Phase 3 | BB |
CARMUSTINE Leland Metheny | Phase 3 | BB |
Irinotecan University of Cincinnati | Phase 3 | BB |
(+)-VINCRISTINE University of Cincinnati | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Romiplostim is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →